Mineralys Therapeutics Announces FDA Acceptance of NDA for Lorundrostat for Treatment of Adults with Hypertension and Topline Explore-OSA Trial Results

Core Insights - The FDA has accepted the New Drug Application (NDA) for lorundrostat, targeting a Prescription Drug User Fee Act (PDUFA) action date of December 22, 2026, for the treatment of adult patients with hypertension [1][2] - The NDA is based on positive clinical data showing favorable safety and blood pressure reduction in adults with hypertension, despite the Explore-OSA trial not demonstrating a reduction in the apnea-hypopnea index (AHI) [1][2] Company Overview - Mineralys Therapeutics, Inc. is a biopharmaceutical company focused on developing treatments for hypertension and related comorbidities, including chronic kidney disease (CKD) and obstructive sleep apnea (OSA) [16][17] - The company's lead product candidate, lorundrostat, is a highly selective aldosterone synthase inhibitor designed to reduce aldosterone levels and is being developed for uncontrolled and resistant hypertension [14][15] Clinical Trial Results - The Explore-OSA trial involved 48 participants with an average body mass index (BMI) of 38.2 kg/m² and an average systolic blood pressure of 142.3 mmHg, showing an 11.1 mmHg reduction in blood pressure with lorundrostat after four weeks [3][4] - Lorundrostat demonstrated a favorable safety profile, with no serum potassium excursions above 5.5 mmol/L, indicating good tolerability [5] Additional Clinical Trials - The Launch-HTN trial is a Phase 3 study assessing lorundrostat in adults with uncontrolled hypertension despite being on multiple antihypertensive medications [6] - The Advance-HTN trial is a Phase 2 study evaluating lorundrostat as an add-on therapy for uncontrolled hypertension, with participants randomized into treatment cohorts [7][8] Market Context - Hypertension affects a significant portion of the population, with less than 50% of patients achieving their blood pressure goals with current medications, highlighting a substantial unmet medical need [12][13] - OSA impacts nearly one billion people globally, with a significant portion of adults with hypertension also suffering from OSA, further complicating treatment options [10][11]